LT2623507T - Morfolino nukleorūgšties darinys - Google Patents
Morfolino nukleorūgšties darinysInfo
- Publication number
- LT2623507T LT2623507T LTEP11829283.8T LT11829283T LT2623507T LT 2623507 T LT2623507 T LT 2623507T LT 11829283 T LT11829283 T LT 11829283T LT 2623507 T LT2623507 T LT 2623507T
- Authority
- LT
- Lithuania
- Prior art keywords
- nucleic acid
- acid derivative
- morpholino nucleic
- morpholino
- derivative
- Prior art date
Links
- -1 Morpholino nucleic acid Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010220865 | 2010-09-30 | ||
| PCT/JP2011/072407 WO2012043730A1 (ja) | 2010-09-30 | 2011-09-29 | モルホリノ核酸誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2623507T true LT2623507T (lt) | 2017-01-25 |
Family
ID=45893168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP11829283.8T LT2623507T (lt) | 2010-09-30 | 2011-09-29 | Morfolino nukleorūgšties darinys |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8969551B2 (lt) |
| EP (1) | EP2623507B1 (lt) |
| JP (1) | JP5831455B2 (lt) |
| KR (1) | KR101764462B1 (lt) |
| CN (1) | CN103154009B (lt) |
| CA (1) | CA2813183C (lt) |
| CY (1) | CY1118435T1 (lt) |
| DK (1) | DK2623507T3 (lt) |
| ES (1) | ES2607603T3 (lt) |
| HR (1) | HRP20170028T1 (lt) |
| HU (1) | HUE030292T2 (lt) |
| LT (1) | LT2623507T (lt) |
| PL (1) | PL2623507T3 (lt) |
| PT (1) | PT2623507T (lt) |
| RS (1) | RS55610B1 (lt) |
| SI (1) | SI2623507T1 (lt) |
| SM (2) | SMT201700038T1 (lt) |
| WO (1) | WO2012043730A1 (lt) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1766010T3 (pl) | 2004-06-28 | 2011-07-29 | Univ Western Australia | Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania |
| EP1855694B1 (en) | 2005-02-09 | 2020-12-02 | Sarepta Therapeutics, Inc. | Antisense composition for treating muscle atrophy |
| EP3133160B1 (en) | 2008-10-24 | 2018-12-12 | Sarepta Therapeutics, Inc. | Exon skipping compositions for dmd |
| WO2011057350A1 (en) | 2009-11-12 | 2011-05-19 | The University Of Western Australia | Antisense molecules and methods for treating pathologies |
| EP2576574A2 (en) * | 2010-05-28 | 2013-04-10 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
| US10017763B2 (en) | 2010-09-03 | 2018-07-10 | Sarepta Therapeutics, Inc. | dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| US9278987B2 (en) | 2011-11-18 | 2016-03-08 | Sarepta Therapeutics, Inc. | Functionally-modified oligonucleotides and subunits thereof |
| JP6542662B2 (ja) | 2012-03-20 | 2019-07-10 | サレプタ セラピューティクス， インコーポレイテッド | オリゴヌクレオチドアナログのボロン酸結合体 |
| CN102702265A (zh) * | 2012-05-14 | 2012-10-03 | 天津特安化学科技有限公司 | 一种固相合成磷酰二胺吗啉代寡核苷酸及方法 |
| NZ775701A (en) | 2013-03-14 | 2022-08-26 | Sarepta Therapeutics Inc | Exon skipping compositions for treating muscular dystrophy |
| AU2014233456B2 (en) | 2013-03-15 | 2019-02-21 | Sarepta Therapeutics, Inc. | Improved compositions for treating muscular dystrophy |
| WO2014189142A1 (ja) | 2013-05-24 | 2014-11-27 | 味の素株式会社 | モルフォリノオリゴヌクレオチドの製造方法 |
| KR20210088009A (ko) | 2013-09-05 | 2021-07-13 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 산성 알파-글루코시다제 내 안티센스-유도된 엑손2 포함 |
| WO2015175977A2 (en) | 2014-05-16 | 2015-11-19 | Geller Bruce L | Antisense antibacterial compounds and methods |
| US10391098B2 (en) | 2014-05-19 | 2019-08-27 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| WO2016060135A1 (ja) | 2014-10-14 | 2016-04-21 | 味の素株式会社 | モルフォリノオリゴヌクレオチドの製造方法 |
| WO2016108930A2 (en) * | 2014-12-31 | 2016-07-07 | Geller Bruce L | Antisense antibacterial compounds and methods |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| DK3297649T5 (da) | 2015-05-19 | 2024-10-07 | Sarepta Therapeutics Inc | Peptid-oligonukleotid-konjugater |
| EP3851531A1 (en) | 2015-06-01 | 2021-07-21 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type vii collagen |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| AU2016302009B2 (en) | 2015-08-05 | 2021-09-30 | Eisai R&D Management Co., Ltd. | Chiral reagents for preparation of homogeneous oligomers |
| EP3359668A4 (en) | 2015-10-09 | 2019-06-05 | Sarepta Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATING DUCHENNE MUSCLE DYSTROPHY AND ASSOCIATED ILLNESSES THEREOF |
| AU2016372026A1 (en) * | 2015-12-15 | 2018-06-21 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| EP3394261A4 (en) | 2015-12-23 | 2019-11-27 | Oregon State University | ANTIBACTERIAL ANTISENSE COMPOUNDS AND METHOD |
| CA3009342A1 (en) | 2015-12-23 | 2017-06-29 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| SG11201808964PA (en) | 2016-04-18 | 2018-11-29 | Sarepta Therapeutics Inc | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
| SG11201809468XA (en) | 2016-04-29 | 2018-11-29 | Sarepta Therapeutics Inc | Oligonucleotide analogues targeting human lmna |
| US11472824B2 (en) | 2016-05-24 | 2022-10-18 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| MA45362A (fr) | 2016-05-24 | 2019-04-10 | Sarepta Therapeutics Inc | Procédés de préparation d'oligomères morpholino de phosphorodiamidate |
| CA3024456A1 (en) | 2016-05-24 | 2017-11-30 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| AU2017271524B2 (en) | 2016-05-24 | 2021-06-24 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| WO2017213854A1 (en) | 2016-05-24 | 2017-12-14 | Sarepta Therapeutics, Inc. | Pharmaceutical composition comprising eteplirsen |
| MX2021008539A (es) | 2016-05-24 | 2022-10-18 | Sarepta Therapeutics Inc | Procesos para preparar oligomeros. |
| KR102523522B1 (ko) | 2016-06-30 | 2023-04-20 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 포스포로디아미데이트 모르폴리노 올리고머의 제조 방법 |
| AU2017330276B2 (en) * | 2016-09-20 | 2022-01-20 | The Regents Of The University Of Colorado, A Body Corporate | Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry |
| WO2018195338A1 (en) | 2017-04-20 | 2018-10-25 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
| JP7218361B2 (ja) * | 2017-09-25 | 2023-02-06 | サレプタ セラピューティクス， インコーポレイテッド | 高速流動合成を介してホスホロジアミデートモルホリノオリゴマーを調製するための方法 |
| US11555189B2 (en) | 2017-10-18 | 2023-01-17 | Sarepta Therapeutics, Inc. | Antisense oligomer compounds |
| AU2019266768B2 (en) | 2018-05-10 | 2024-02-29 | Nippon Shinyaku Co., Ltd. | Method for producing oligonucleic acid compound |
| WO2021025899A1 (en) | 2019-08-02 | 2021-02-11 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer pharmaceutical compositions |
| CN114981280A (zh) | 2019-11-13 | 2022-08-30 | 日本新药株式会社 | 寡核苷酸化合物的制造方法 |
| US20230018780A1 (en) | 2019-11-13 | 2023-01-19 | Nippon Shinyaku Co., Ltd. | Method for producing oligonucleic acid compound |
| JP2023541091A (ja) * | 2020-07-10 | 2023-09-28 | チャンヂョウ シンザオール ファーマシューティカルズ カンパニー リミテッド | オリゴヌクレオチドを調製するための方法 |
| WO2022230954A1 (ja) * | 2021-04-28 | 2022-11-03 | 日本新薬株式会社 | オリゴ核酸化合物の製造方法 |
| MX2023012559A (es) | 2021-04-30 | 2023-12-15 | Sarepta Therapeutics Inc | Métodos de tratamiento para la distrofia muscular. |
| US20240318179A1 (en) | 2021-10-22 | 2024-09-26 | Murdoch University | Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases |
| AU2022424485A1 (en) | 2021-12-27 | 2024-07-11 | Nippon Shinyaku Co., Ltd. | Method for producing oligonucleic acid compound |
| WO2023167908A1 (en) * | 2022-03-01 | 2023-09-07 | Eisai R&D Management Co., Ltd. | Bis-protected, activated guanine monomers |
| EP4493693A1 (en) | 2022-03-17 | 2025-01-22 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer conjugates |
| EP4511385A1 (en) | 2022-04-22 | 2025-02-26 | Entrada Therapeutics, Inc. | Cyclic peptides for delivering therapeutics |
| WO2024064237A2 (en) | 2022-09-21 | 2024-03-28 | Sarepta Therapeutics, Inc. | Dmd antisense oligonucleotide-mediated exon skipping efficiency |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0506830B1 (en) | 1989-12-20 | 2005-12-14 | Avi Biopharma, Inc. | Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages |
| JP2005255530A (ja) * | 2004-03-09 | 2005-09-22 | Japan Science & Technology Agency | ２−チオウリジン誘導体 |
| EP2024499B1 (en) * | 2006-05-10 | 2017-10-25 | Sarepta Therapeutics, Inc. | Oligonucleotide analogs having cationic intersubunit linkages |
| US8076476B2 (en) * | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
| CA2884340C (en) | 2007-11-15 | 2017-07-25 | Sarepta Therapeutics, Inc. | Method of synthesis of morpholino oligomers |
-
2011
- 2011-09-29 KR KR1020137011017A patent/KR101764462B1/ko active IP Right Grant
- 2011-09-29 EP EP11829283.8A patent/EP2623507B1/en active Active
- 2011-09-29 CA CA2813183A patent/CA2813183C/en active Active
- 2011-09-29 DK DK11829283.8T patent/DK2623507T3/da active
- 2011-09-29 JP JP2012536551A patent/JP5831455B2/ja active Active
- 2011-09-29 US US13/876,194 patent/US8969551B2/en active Active
- 2011-09-29 LT LTEP11829283.8T patent/LT2623507T/lt unknown
- 2011-09-29 RS RS20170057A patent/RS55610B1/sr unknown
- 2011-09-29 ES ES11829283.8T patent/ES2607603T3/es active Active
- 2011-09-29 WO PCT/JP2011/072407 patent/WO2012043730A1/ja active Application Filing
- 2011-09-29 SM SM20170038T patent/SMT201700038T1/it unknown
- 2011-09-29 PT PT118292838T patent/PT2623507T/pt unknown
- 2011-09-29 HU HUE11829283A patent/HUE030292T2/en unknown
- 2011-09-29 PL PL11829283T patent/PL2623507T3/pl unknown
- 2011-09-29 CN CN201180047487.3A patent/CN103154009B/zh active Active
- 2011-09-29 SI SI201131069A patent/SI2623507T1/sl unknown
-
2017
- 2017-01-10 CY CY20171100027T patent/CY1118435T1/el unknown
- 2017-01-10 HR HRP20170028TT patent/HRP20170028T1/hr unknown
- 2017-01-19 SM SM201700038T patent/SMT201700038B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101764462B1 (ko) | 2017-08-02 |
| RS55610B1 (sr) | 2017-06-30 |
| US20130197220A1 (en) | 2013-08-01 |
| SMT201700038B (it) | 2017-03-08 |
| PT2623507T (pt) | 2016-12-23 |
| JPWO2012043730A1 (ja) | 2014-02-24 |
| CN103154009A (zh) | 2013-06-12 |
| JP5831455B2 (ja) | 2015-12-09 |
| CA2813183C (en) | 2017-09-19 |
| EP2623507A4 (en) | 2014-03-19 |
| CY1118435T1 (el) | 2017-06-28 |
| SMT201700038T1 (it) | 2017-03-08 |
| EP2623507A1 (en) | 2013-08-07 |
| PL2623507T3 (pl) | 2017-03-31 |
| EP2623507B1 (en) | 2016-11-02 |
| HUE030292T2 (en) | 2017-04-28 |
| CN103154009B (zh) | 2015-06-10 |
| US8969551B2 (en) | 2015-03-03 |
| WO2012043730A1 (ja) | 2012-04-05 |
| KR20130143045A (ko) | 2013-12-30 |
| CA2813183A1 (en) | 2012-04-05 |
| SI2623507T1 (sl) | 2017-04-26 |
| ES2607603T3 (es) | 2017-04-03 |
| HRP20170028T1 (hr) | 2017-03-24 |
| DK2623507T3 (da) | 2017-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT2623507T (lt) | Morfolino nukleorūgšties darinys | |
| GB2494239B (en) | Nucleic acid amplification | |
| DK2922554T3 (en) | Terminalt modificeret rna | |
| PL2612917T3 (pl) | Antysensowy kwas nukleinowy | |
| IL231983A0 (en) | Dna containing tricyclo-phosphorothioate | |
| SG10201802883UA (en) | Nucleic acid amplification | |
| IL223642A (en) | Inorganic elements to enhance gene expression | |
| ZA201206793B (en) | Nucleic acid complexes | |
| LT2993232T (lt) | Nukleorūgščių gavimo būdas | |
| HK1188608A1 (en) | Dna expression construct dna | |
| GB2479833B (en) | Modified nucleotides | |
| GB201120989D0 (en) | Genetic test | |
| EP2682462A4 (en) | (Nucleic acid) polysaccharide COMPLEX | |
| ZA201400918B (en) | Pyrrolidine-3-ylacetic acid derivative | |
| EP2594592A4 (en) | COMPLEX (NUCLEIC ACID) -POLYSACCHARIDE | |
| EP2589656A4 (en) | GENEINSETZUNGSVERFAHREN | |
| GB201107286D0 (en) | Nucleic acid preparation | |
| GB201001940D0 (en) | Nucleic acid isolation | |
| GB201105387D0 (en) | Nucleic acid probes | |
| GB201009654D0 (en) | Nucleic acid methyltransferase | |
| AU2011902654A0 (en) | Nucleic acid complex | |
| GB201014572D0 (en) | Genetic tests | |
| EP2799424A4 (en) | 2-FLUORPHENYLPROPIONSÄUREDERIVAT | |
| GB201004862D0 (en) | DNA amplification | |
| GB201115254D0 (en) | Genetic test |